oxycodone CR + oxycodone IR + Tapentadol ER (CG5503) + Tapentadol IR (CG5503) + Tapentadol IR (CG5503) + placebo + placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Joint Diseases
Conditions
Joint Diseases, Arthritis, Osteoarthritis
Trial Timeline
Oct 1, 2008 → Jul 1, 2009
NCT ID
NCT00784277About oxycodone CR + oxycodone IR + Tapentadol ER (CG5503) + Tapentadol IR (CG5503) + Tapentadol IR (CG5503) + placebo + placebo
oxycodone CR + oxycodone IR + Tapentadol ER (CG5503) + Tapentadol IR (CG5503) + Tapentadol IR (CG5503) + placebo + placebo is a phase 3 stage product being developed by Johnson & Johnson for Joint Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT00784277. Target conditions include Joint Diseases, Arthritis, Osteoarthritis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00784277 | Phase 3 | Completed |
Competing Products
6 competing products in Joint Diseases
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| 0.75% bupivacaine + .75% bupivacaine + .75% bupivacaine | SI-BONE | Approved | 77 |
| Durvalumab + Tremelimumab | AstraZeneca | Phase 1/2 | 41 |
| etanercept + placebo | Pfizer | Phase 2 | 51 |
| VANCOMYCIN + CEFTRIAXONE + CLINDAMYCIN + SULFAMETHOXAZOLE AND TRIMETHOPRIM (CO-TRIMOXAZOLE) + FLUOROQUINOLONE + LINEZOLID + RIFAMPIN | Pfizer | Phase 2 | 51 |
| HOE140 Icatibant | Sanofi | Phase 2 | 51 |
| Methylprednisoloneacetate + Lidocaine | Lundbeck | Phase 2 | 49 |